Shuaiya Ma
Zhengzhou, 450008, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Immune checkpoint TIM-3 in tumor immunotherapy.
Journal: Acta biochimica et biophysica Sinica
Published: December 24, 2025
Age-dependent prognostic significance of neutrophil-to-HDL ratio in hepatocellular carcinoma patients.
Journal: Frontiers in oncology
Published: April 30, 2025
Association of Lipid and Inflammatory Profiles With Tumor Stage in Hepatocellular Carcinoma.
Journal: Cancer medicine
Published: January 14, 2025
Palmitoylation of TIM-3 promotes immune exhaustion and restrains antitumor immunity.
Journal: Science immunology
Published: November 15, 2024
Urolithin A Hijacks ERK1/2-ULK1 Cascade to Improve CD8+ T Cell Fitness for Antitumor Immunity.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: December 21, 2023
Identification of a small-molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical mouse models.
Journal: Science translational medicine
Published: November 15, 2023
Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8+ T cell exhaustion and anti-PD-1 resistance.
Journal: Cell reports. Medicine
Published: October 28, 2022
Intrinsic PD-L1 promotes antitumor activity of CD8+ cytotoxic T lymphocytes via in cis interaction with CD80.
Journal: Cancer communications (London, England)
Published: February 10, 2022
Spatial distribution and functional analysis define the action pathway of Tim-3/Tim-3 ligands in tumor development.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: July 15, 2021
Showing 1-9 of 9
Last Updated: 09/26/2026